il y aura un vote ! voyez cette news de début d'année :
" January 8th, 2009
InSite Vision Incorporated (AMEX:ISV) announced that the U.S. Food and
Drug Administration (FDA) Dermatologic and Ophthalmic Drugs Advisory
Committee has voted unanimously to recommend approval of Bausch &
Lomb’s besifloxacin ophthalmic suspension, 0.6%, for the treatment of
bacterial conjunctivitis, a product that utilizes InSite Vision’s
DuraSite
patented drug delivery system."
L'Advisory Committee a voté à l'unanimité pour recommander l'approbation du besifloxacin .......